Loading...
Patients with high-risk localized prostate cancer who undergo curative intent treatment are at significant risk for disease recurrence within 5 years, regardless of whether their treatment involved surgery or a combination of radiotherapy and androgen deprivation therapy (ADT). Perioperative ADT is not routinely used in men undergoing radical prostatectomy, but success with ADT plus apalutamide (an androgen receptor pathway inhibitor) in advanced disease has prompted interest in moving this combination earlier.
In this industry-funded, phase 3 trial, 2100 men undergoing radical prostatectomy for high-risk localized or locally advanced prostate cancer were randomly assigned to receive perioperative ADT in combination with either apalut…